The latest news from academia, regulators
research labs and other things of interest
Posted: May 14, 2008
Blood Clotting Nanotechnology Picked by U.S. Military as First-Line Hemostatic Treatment
(Nanowerk News) Z-Medica Corporation
(Z-Medica), a medical products company focused on innovative blood clotting
nanotechnologies, announced that the United States Department of Defense
has selected the company's newest hemostatic product, QuikClot® Combat
Gauze™ brand, for all military services as the first-line hemostatic
treatment for life-threatening hemorrhage that is not amenable to
tourniquet placement. Bleeding is the number one cause of death for
soldiers injured in battle and QuikClot® products offer the most
effective solution to severe blood loss outside the operating room setting.
They have been proven in battlefield use and, with more than one million
units deployed, are the leading hemostatic agents in the field.
The Committee on Tactical Combat Casualty Care (CoTCCC) made the
decision to recommend QuikClot® Combat Gauze™ after reviewing test
reports on a number of hemostatic products. QuikClot® Combat Gauze™
was the only one of these products tested by both the Naval Medical
Research Center and the U.S. Army Institute for Surgical Research. In
addition to test efficacy, the committee sited a number of other factors in
according QuikClot® Combat Gauze™ the number one position:
Preference for the gauze delivery format, which is familiar to combat
Ability of QuikClot® Combat Gauze™ to be shaped to any wound and
to reach bleeding vessels in penetrating wounds.
Ease of removal once hemostasis has been achieved.
"Z-Medica's approach to product innovation has always been to listen to
the voice of our customer and to focus our research & development efforts
on delivering life-saving products that meet their needs," said Z-Medica
CEO Raymond J. Huey. "With QuikClot® Combat Gauze™ we have provided a
product that is virtually 100% effective in a very intuitive format that
can be applied quickly and simply by anyone."
QuikClot® Combat Gauze™ combines surgical gauze with a proprietary
inorganic material that stops arterial and venous bleeding in seconds --
even more rapidly in this format than earlier Z-Medica products. Based on a
different mineral than zeolite-based QuikClot® products, it generates no
heat. It shares the benefit of being inert and non-allergenic. QuikClot®
Combat Gauze™ comes in rolls four yards long by three inches wide.
In addition to the military testing, the new product was tested in
pre-clinical trials at the University of California, Santa Barbara, the
University of Massachusetts Medical School and at various field facilities.
It has 510(k) clearance from the U.S. Food & Drug Administration. The
United States Department of Defense has awarded Z-Medica a $3.2 million
grant for large-scale testing of the product on penetrating wounds. These
multi-center clinical trials will take place during 2008.
Earlier QuikClot® products are in use by all branches of the U.S.
Military, by first responders and security agencies across the U.S. and in
36 countries worldwide, with more than a million units in distribution.
Z-Medica recently launched its first products for consumers.
Founded in April 2002, Z-Medica Corporation is a medical products
company focused on innovative blood clotting technologies -- hemostatic
solutions that save lives. QuikClot® was developed in cooperation with
the Office of Naval Research (ONR), the U.S. Marine Corps Warfighting
Laboratory, the U.S. Marine Corps Systems Command and university hospitals.
It represents the first and most effective solution to severe blood loss
outside the operating room setting. Z-Medica serves several global vertical
markets, including military, first responder, homeland and private
security. The U.S. Department of Homeland Security's Office of Grants &
Training added 'hemostatic agent' to its 2006 Authorized Equipment List
(AEL), qualifying QuikClot® for purchase using grant dollars, subject to
each State's administrative agency's approval. And, in 2007, the National
Tactical Officers Association gave the company and its new products their
coveted official seal of "NTOA member tested and approved". In addition to
QuikClot® Combat Gauze™, the company is fully engaged in accelerating
the development and distribution of QuikClot® brand hemostatic agent,
QuikClot® ACS+™, QuikClot® 1st Response™, QuikClot® Sport™,
QuikClot® Sport Silver™ (antimicrobial) and related products.